Spero Therapeutics (SPRO) news

Spero Therapeutics - May offer up to $300 mln in securities - SEC filing

Spero Therapeutics, Inc. (NASDAQ: SPRO), a clinical-stage biopharmaceutical company focused on developing next-generation immunology and inflammation therapies, has filed with the U.S. Securities and Exchange Commission (SEC) to offer up to $300 million in securities, according to a recent SEC…

Innovent announces 2026 interim results and business updates

Innovent Biologics (HK:1801) reported strong first-half 2026 financial results, with total revenue rising 44.8% year on year to RMB8.62 billion and product revenue increasing 56.7% to RMB8.20 billion. The performance was driven by the company’s dual-engine growth strategy, combining a broad…

Spero Therapeutics - HCRX to receive quarterly principal and interest payments derived from the GSK payments due to Spero until loan repaid

Spero Therapeutics, Inc. (NASDAQ: HCRX) has disclosed a financial arrangement in which the company will receive quarterly principal and interest payments derived from payments it is due from GlaxoSmithKline (GSK). These payments will continue until the loan is fully repaid. The structure of this…

Spero Therapeutics - updates cash runway guidance into second half of 2029

Spero Therapeutics announces $105 million non-recourse non-dilutive financing backed by a portion of Utebzi milestones & royalties

Spero Therapeutics, Inc. has announced a $105 million non-recourse, non-dilutive financing arrangement, supported by a portion of future milestones and royalties from its Utebzi program. This financing structure allows the company to access capital without issuing additional equity or incurring…